Skip to main content
Premium Trial:

Request an Annual Quote

Stemina Biomarker Discovery Raises $1M in Angel Funds

NEW YORK (GenomeWeb News) – Stemina Biomarker Discovery said this week that it has raised $1 million in angel investments to further develop its product for assessing drug toxicity in the developing human embryo.

Angel groups DaneVest Tech Fund Advisors, Phenomenelle Angels, and Wisconsin Investment Partners all contributed to the financing.

Stemina said that it plans to raise a total of $3 million in the financing round. In addition, the company said that it was recently awarded a $150,000 grant from the National Science Foundation.

Stemina, based in Madison, Wisc., will use the funds to broaden commercialization of its devTOX screen, expand the company's scientific and business development teams, finance additional equipment purchases, and cover operating expenses.

DevTox is a human embryonic stem cell- and metabolomics-based screen for assessing the toxicity of drugs on the developing human embryo. The company uses mass spectrometry to analyze small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells, in response to drugs, injury, or disease.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.